Print this page
Friday, 08 September 2017 20:53

Anticoagulation news items. Week commencing 4th September 2017

Pharmacovigilance Risk Assessment Committee (PRAC) confirms its previous conclusion on risk of inhibitor development with factor VIII medicines

European Medicines Agency

The PRAC has confirmed its previous conclusion that there is no clear and consistent evidence of a difference in the incidence of inhibitor development between the two classes of factor VIII medicines: plasma-derived and made with recombinant DNA technology.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: